|Bid||26.86 x 0|
|Ask||27.75 x 0|
|Day's Range||26.73 - 27.78|
|52 Week Range||7.45 - 32.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.64|
MARKHAM, ON , July 18, 2018 /CNW/ - MedReleaf Corp. ("MedReleaf") (LEAF.TO) is pleased to announce that, at the special meeting of shareholders of MedReleaf held today (the "Meeting"), the shareholders of MedReleaf voted in favour of a special resolution to approve the proposed transaction, pursuant to which, among other things, Aurora Cannabis Inc. ("Aurora") will acquire all of the issued and outstanding shares of MedReleaf, by way of a court-approved plan of arrangement (the "Arrangement") as previously announced on May 14, 2018 . The Arrangement required approval by 66⅔% of the votes cast by shareholders present in person or represented by proxy at the Meeting.
MARKHAM, ON , July 12, 2018 /CNW/ - MedReleaf Corp. (LEAF.TO) ("MedReleaf" or the "Company"), in collaboration with the Ontario Clinical Oncology Group ("OCOG") today announced it will sponsor a cancer trial to improve the management of cancer pain using medical grade cannabis oil. The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven , a specialist in pain management and palliative care is the Principal Investigator.
MARKHAM, ON , July 12, 2018 /CNW/ - MedReleaf Corp. (LEAF.TO) ("MedReleaf" or the "Company"), today announced that it has entered into a Memorandum of Understanding ("MOU") with the British Columbia Liquor Distribution Branch ("BCLDB") to supply the Province with high quality adult recreational-use cannabis products. Under the terms of the MOU, MedReleaf has agreed to supply the BCLDB with cannabis products in a variety of formats including dried flower and capsules. MedReleaf will be represented on British Columbia's on-line and brick and mortar retail outlets under the San Rafael '71, AltaVie and Woodstock brands.
MARKHAM, ON , July 11, 2018 /CNW/ - MedReleaf Corp. (LEAF.TO) ("MedReleaf" or the "Company") today announced that it has received certification under the European Medical Agency's Good Manufacturing Practices ("EU GMP") Standards for its Markham facility from authorities in Cologne, Germany to make a first export of its products into Germany and has completed its first shipment of medical cannabis to Cannamedical Pharma GmbH ("Cannamedical"). "With the completion of our first shipment to Germany and ongoing shipments scheduled, MedReleaf is already among the leading exporters of cannabis to the European Union," said Neil Closner , CEO of MedReleaf.
MARKHAM, ON , July 6, 2018 /CNW/ - MedReleaf Corp. (LEAF.TO) ("MedReleaf" or the "Company") is pleased to announce that Institutional Shareholder Services, Inc. ("ISS") and Glass, Lewis & Co. ("GlassLewis"), two leading independent proxy advisory firms, have both recommended that MedReleaf shareholders vote FOR the previously announced arrangement (the "Arrangement") between MedReleaf and Aurora Cannabis Inc. ("Aurora"), whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf (the "Transaction"). In their assessment of the Arrangement, both ISS and Glass Lewis cite the sound strategic merit for the Transaction providing significantly increased scale, production capacity and expanded product development capabilities in anticipation of legalized adult use cannabis consumption in Canada , the offer premium and the transaction process supervised by the special committee formed by the Board of Directors as factors in supporting their FOR recommendation.
MARKHAM, ON , July 5, 2018 /CNW/ - MedReleaf Corp. (LEAF.TO) ("MedReleaf" or the Company") today announced that it has completed a supply agreement with the Alberta Gaming, Liquor & Cannabis Commission ("AGLC") to supply high quality adult recreational-use cannabis products. Under the terms of the agreement, MedReleaf is committed to supplying the AGLC with cannabis products in a variety of formats including dried flower and capsules. MedReleaf will be represented on Alberta's cannabis store shelves and online through www.albertacannabis.org under both the San Rafael '71 and AltaVie brands.
MARKHAM, ON , June 20, 2018 /CNW/ - MedReleaf Corp. ("MedReleaf" or the "Company") (LEAF.TO), today announced that the Company has been granted an interim order from the Ontario Superior Court of Justice (Commercial List) authorizing various matters, including the holding of a special meeting of MedReleaf shareholders to consider the previously announced arrangement (the "Arrangement") between MedReleaf and Aurora Cannabis Inc. ("Aurora") and the mailing of a management information circular (the "Circular") in respect of the previously announced transaction whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf (the "Transaction"). As described in the Circular, MedReleaf will be seeking shareholder approval for the Arrangement under the Business Corporations Act ( Ontario ) (the "Arrangement Resolution"). The special meeting of MedReleaf shareholders to consider the Arrangement Resolution will be held on Wednesday, July 18, 2018 at 1:00 p.m. ( Toronto time) at the offices of Stikeman Elliot LLP, 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario .
NEW YORK , June 5, 2018 /PRNewswire/ -- Children with Complex Movement Disorders (CMD) see a "significant" improvement after treatment with medical cannabis, a new study using Tikun Olam 's high-CBD, ...
MedReleaf Corp. and BioPharma Services Inc. today announced they have entered into an exclusive agreement to conduct clinical research for cannabis and cannabis derived products.
EDMONTON and MARKHAM, ON , May 25, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (ACB.TO) and MedReleaf Corp. ("MedReleaf") (LEAF.TO) today announced the filing on SEDAR of the arrangement agreement dated May 14, 2018 between Aurora and MedReleaf (the "Original Agreement"), as amended by an amending agreement (the "Amending Agreement"), and the material change reports in respect of the previously announced transaction whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf (the "Material Change Reports"). Aurora and MedReleaf have agreed to amend the Original Agreement to include, in the consideration payable to holders of MedReleaf's common shares, (each a "MedReleaf Share"), $0.000001 in cash for each MedReleaf Share. As a result, the consideration under the arrangement has been increased from 3.575 Aurora common shares for each MedReleaf Share to 3.575 Aurora common shares and $0.000001 in cash for each MedReleaf Share. Taxable Canadian resident MedReleaf shareholders will be entitled to elect to receive tax-deferred roll-over treatment in connection with the acquisition by Aurora of their MedReleaf Shares. If a MedReleaf shareholder does not, or is unable to, make an election, then Aurora's acquisition cost for such shareholder's MedReleaf Shares will generally be equal to the fair market value of such shares.
MedReleaf and the CFLAA recognize the opportunity to collaborate on this important study which will bring greater awareness to the potential health benefits of using medical cannabis in the treatment of ailments that include chronic pain.
Aurora Cannabis on Monday agreed to buy fellow Canadian pot stock MedReleaf for $2.5 billion, a record industry deal. Canada's Canopy Growth plans a NYSE listing.
Some of Canada’s richest marijuana investors just got a little richer -- at least on paper. The biggest shareholders in Markham, Ontario-based pot grower MedReleaf Corp. now have stakes worth more than C$200 million ($156 million) each following Aurora Cannabis Inc.’s acquisition for about C$2.9 billion in stock, the largest deal in the sector. MedReleaf holders, including Gibraltar-based investor Tarik Ouass, along with Raymond Leach and Stephen Arbib have combined stakes worth about C$1.74 billion, based on the deal valuations.
Aurora Cannabis Inc will buy rival MedReleaf Corp for C$3.2 billion ($2.51 billion) in the biggest deal yet to unify major Canadian pot growers, as the country moves toward legalizing marijuana for recreational use. Canada's relaxed regulations, a mature industry and free-flowing capital have offered firms a unique opportunity to advance research without the legal and political risks that bog down growers in the United States and elsewhere. Canadian regulators have granted over 70 firms licenses to produce and sell medical marijuana, with more than half granted in 2017 or 2018.
EDMONTON and MARKHAM, ON , May 14, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (ACB.TO) and MedReleaf Corp. ("MedReleaf") (LEAF.TO) are pleased to announce that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted basis (the "Transaction"). Under the terms of the Arrangement Agreement, holders of MedReleaf common shares will receive 3.575 common shares of Aurora for each MedReleaf common share held (the "Exchange Ratio").